Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | KLK7 | P49862 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.33 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19711763 | 0.88 | ALDH1A1 (0.42) | AKR1C3PTGDR2 | |
| SCHEMBL19702818 | 0.88 | PTGDR2 (0.40) | PTGDR2SMN1; SMN2KLK7TDP1SLC16A3 | |
| SCHEMBL20575340 | 0.82 | AKR1C3 (0.36) | AKR1C3AKR1C2PTGDR2KLK7 | |
| SCHEMBL19702816 | 0.80 | PTGDR2 (0.40) | PTGDR2SMN1; SMN2KLK7TDP1SLC16A3 | |
| SCHEMBL17777911 | 0.77 | NPBWR1 (0.38) | AKR1C3AKR1C2NPBWR1 | |
| SCHEMBL17777763 | 0.76 | ALDH1A1 (0.44) | PTGDR2 | |
| SCHEMBL19659812 | 0.74 | GAA (0.33) | SMN1; SMN2 | |
| SCHEMBL19702820 | 0.73 | PTGDR2 (0.41) | PTGDR2SMN1; SMN2KLK7TDP1 | |
| SCHEMBL17777923 | 0.73 | ASIC1 (0.40) | SMN1; SMN2KLK7 | |
| SCHEMBL19659649 | 0.71 | KLK7 (0.35) | SMN1; SMN2KLK7TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200407364-A1 | FUSED BICYCLIC COMPOUNDS | AKARNA THERAPEUTICS LTD (GB) | 2020-12-31 | — | — | US | disclosed |
| US-20180346473-A1 | FUSED BICYCLIC COMPOUNDS | AKARNA THERAPEUTICS, LTD. (TW) | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346473-A1 | FUSED BICYCLIC COMPOUNDS | BICRA, PAICS, NDC1 | AKR1C3 2360/4885AKR1C2 1759/4885PTGDR2 2695/4885 |
| US-20200407364-A1 | FUSED BICYCLIC COMPOUNDS | BICRA, PAICS, NDC1 | AKR1C3 2360/4885AKR1C2 1759/4885PTGDR2 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.